Abstract 25
Flavobacterium psychrophilum is the causative agent of Rainbow Trout Fry Syndrome which 26 has had a major impact on global salmonid aquaculture. Recent outbreaks in Atlantic salmon 27 in Scotland and Chile have added to the need for a vaccine to protect both salmon and trout. 28 At present no licensed vaccines are available in Europe, leaving antibiotics as the only course 29 of action to contain disease outbreaks. Outbreaks generally occur in fry at temperatures 30 between 10-15 °C. Recently outbreaks in larger fish have given added impetus to the 31 development of a vaccine which can provide long term protection from this highly 32 heterogeneous pathogen. Most fish injectable vaccines are formulated with oil emulsion 33 adjuvants to induce strong and long lasting immunity, but which are known to cause side 34 effects. Alternative adjuvants are currently sought to minimise these adverse effects. 35
The current study was performed to assess the efficacy of a polyvalent, whole cell vaccine 36 containing formalin-inactivated F. psychrophilum to induce protective immunity in Atlantic 37 salmon. The vaccine was formulated with an adjuvant containing squalene and aluminium 38 hydroxide, and was compared to a vaccine formulated with a traditional oil adjuvant, 39
Montanide ISA 760VG, and a non-adjuvanted vaccine. Duplicate groups of salmon (23.5 ± 40 6.8 g) were vaccinated with each of the vaccine formulations or phosphate buffered saline by 41 intraperitoneal injection. Fish were challenged by intramuscular injection with F. 42 psychrophilum six weeks post-vaccination to test the efficacy of the vaccines. Cumulative 43 mortality reached 70% in the control salmon, while the groups of salmon that received 44 vaccine had significantly lower mortality than the controls (p = 0.0001), with no significant 45 difference in survival between vaccinated groups. The squalene/alum adjuvant was safe, more 46 readily metabolised by the fish and induced less histopathological changes than the traditional 47 oil adjuvant. 48
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Introduction 51
Rainbow trout fry syndrome (RTFS), caused by Flavobacterium psychrophilum, is one of the 52 most significant disease problems facing the salmonid aquaculture industry worldwide [1] . 53
Rainbow trout (Oncorhynchus mykiss) are the species most affected although there are 54 increasing problems in Atlantic salmon (Salmo salar) hatcheries in Scotland and Chile. 55
Disease episodes tend to occur between 10-15 ºC, with necrotic lesions often seen on the skin 56 surrounding the dorsal fin and tail, while in very small fish no clinical signs are apparent and 57 death occurs due to septicaemia. F. psychrophilum is a highly heterogeneous pathogen, which 58 makes development of cross-protective vaccines to control this devastating disease 59 problematic [2] . Antibiotic treatment is relied on to treat outbreaks, which has led to increased 60 levels of antibiotic resistance in F. psychrophilum isolates [3] [4] [5] , highlighting the urgent need 61 for prophylactic treatments for RTFS. 62
The majority of inactivated whole cell or sub-unit vaccines available to the aquaculture 63 industry are formulated in oil emulsions [6] . Adjuvanted vaccines are injected 64 intraperitoneally, and provide protection via a prolonged release of antigen from the oil 65 component stimulating primarily local inflammatory reactions followed by a systemic 66 immune response [7] . While oil-based adjuvants have provided increased efficacy of vaccines 67
for aquaculture, problems with side-effects at injection sites have resulted in the down grading 68 of fish at harvest due to adhesions between the body wall and abdominal organs and spinal 69 deformities [8] [9] [10] . Therefore, there is a need to develop adjuvants for use in injectable 70 vaccines for salmonids, which balance the efficacy-safety profile. A previous study using an 71 adjuvant containing squalene and aluminium hydroxide to formulate a vaccine for treatment 72 
Atlantic Salmon Fry 85
Atlantic salmon eggs were supplied by AquaGen (Norway) and transported on ice to the 86 aquarium at the Institute of Aquaculture, Stirling. On arrival eggs were subjected to an 87 iodophor surface disinfectant treatment according to the manufacturer's instructions 88 (Buffodine, Evans Vanodine, UK). Five replicates of 10 eggs were removed and confirmed to 89 be F. psychrophilum free using a nested PCR for the 16S rRNA gene with modifications 90 [12, 13] . The eggs were maintained in flow-through de-chlorinated tap water at 10 ºC until 91 hatch, and thereafter maintained in a 100 L flow-through tank (5 L min -1 ). The fry were fed to 92 satiation daily (Inicio feed, 1.1 mm, BioMar, UK). All experimental procedures with live fish 93 were carried out in accordance with the UK Animals (Scientific Procedures) Act, 1986 and 94 associated guidelines, EU Directive 2010/63/EU for animal experiments and were approved 95 by the Ethics Committee of the Institute of Aquaculture, University of Stirling, UK. 96
Preparation of formalin inactivated bacteria 98
Two isolates of F. psychrophilum recovered from trout and one recovered from salmon in the 99 UK in 2013 were used to make the whole cell vaccine (Table 1) Fish (23.5 ± 6.8 g) were randomly separated into 100 L flow-through tanks with 112 aeration at 15 ºC. The experimental design of the vaccination trial is summarised in Table 2 . 113
Fish were anaesthetised with benzocaine (Sigma, 0.004%) and given one of the vaccine 114 formulations by intra-peritoneal injection (50 µl per fish). Control groups were injected i.p. 115 with 50 µl of sterile PBS. Fish were euthanized by an over-dose of benzocaine and sampling 116 carried out at various time points (Table 2) . Tissues (spleen, liver, kidney, intestine and heart) 117 from three fish per replicate were collected and immediately fixed in formaldehyde in PBS 118 (100 mL 35% formaldehyde and 900 mL DW) for histology. Head-kidney from three fish per 119 duplicate group (n=6) was placed immediately in RNA-later (Sigma) and stored at 4 ºC 120 overnight. RNA-later was removed and tissues stored at -70 ºC until RNA extraction. Blood 121 was sampled from the caudal vein using a 23 G needle and syringe from three fish per 122 duplicate group (n=6) stored overnight at 4 ºC, centrifuged at 3000 x g 5 min for collection of 123 serum which was stored at -20 ºC until analysis. 124 125 Diagnostics Ltd., 1/33 in PBS, 1h) followed by incubation with anti-mouse-HRP (1/4000, 148
Sigma, 1h). The absorbance was read on a BioTek HT Synergy spectrophotometer at 450 nm. 149 150
SDS-PAGE and Western blotting 151

Sodium dodecyl sulphate polyacramide gel electrophoresis (SDS-PAGE) 152
Suspensions of the three vaccine isolates and a heterologous isolate of F. psychrophilum were 153 aliquoted into 1.5 ml microcentrifuge tubes (1 mL of 2 x 10 8 cfu/mL), and centrifuged for 15 154 min at 3000 × g. Bacterial pellets were resuspended in 100 µl of DW and 30 µl of 5 X sample 155 buffer (250mM Tris-HCl, 30% glycerol, 10% SDS, 0.5M dithiothreitol, 0.2% bromophenol 156 blue) and boiled for 15 min. Finally, the samples were centrifuged at 10,000 × g for 10 min 157 prior to analysis of the supernatants. A preparation of broad-range molecular weight markers 158 The gene expression data were normalised to the reference genes and expressed as a 231 The eggs were free of F. psychrophilum (Fig. S1a) and F. psychrophilum was detected in 268 moribund and dead fish sampled during the challenge (Fig. S1b) . 269 270
Specific antibody response 271
Antibody levels (IgM) were measured at a 1:64 dilution as this gave the best resolution 272 between groups. Antibody levels of vaccinated fish screened against a F. psychrophilum 273 vaccine isolate (AVU-3S/13, serotype FpT) 6 wpv were significantly elevated in the group 274 which received the Montanide adjuvanted vaccine (p = 0.002) when compared to fish that 275 received either PBS, unadjuvanted vaccine or vaccine emulsified with squalene/alum (Fig. 2  276 A). The levels of IgM to a heterologous isolate of F. psychrophilum (AVU-1T/07, serotype 277 Th) were also significantly elevated in both groups of fish given the vaccine emulsified with 278 adjuvants compared to fish injected with PBS or the unadjuvanted vaccine (p = 0.010) (Fig. 2  279   B) . 
SDS-PAGE and Western blot 287
Distinct bands ranging from 10-250 kDa were evident in the SDS-PAGE profiles of the F. 288 psychrophilum isolates used to prepare the polyvalent vaccine (and a heterologous isolate 289 AVU-1T/07) following staining with Coomassie (Fig 3A) . Banding profiles of the isolates 290 were similar, with the exception of a slight difference in the band between 20-25kDa in the 291 heterologous isolate. When blots of these isolates were incubated with immune sera sampled 292 6 wpv (pooled sera with a titre of 512 by ELISA), the strongest staining was seen with serum 293 from fish vaccinated with the Montanide and squalene/alum vaccine preparations (Fig. 3B)  294 reflecting the results obtained by ELISA. Bands ranging from 15 to 250 kDa were recognised 295 by the Montanide group, whereas the serum from fish given unadjuvanted vaccine recognised 296 bands between 37-250 kDa with much weaker staining. This was also the case with serum 297 from fish given vaccine emulsified with squalene/alum adjuvant, with bands recognised 298 between 37-75 kDa. These bands also stained weakly in control fish administered PBS. 
Histology 311
Internal organs of spleen, kidney, liver, heart and digestive tract were examined histologically 312 for signs of inflammation or adverse reactions to the vaccine/adjuvants six weeks post-313 vaccination. No histological changes were observed in the PBS injected fish. In fish 314 administered the unadjuvanted vaccine, inflammatory cell accumulation was observed at the 315 injection site and around the spleen, intestine and pancreatic tissue in one of the six fish 316 sampled (Fig. 4 A, 
B). Another two fish had very few inflammatory cells in normal adipose 317
A B tissue around the pancreas. Vaccine emulsified with squalene and alum induced inflammatory 318 cell infiltration higher than the FKC group but distantly less than the groups given vaccine 319 formulated with Montanide ISA760VG adjuvant (Table 4) . Lipid droplets were observed 320 among the inflammatory cells, which originated from the squalene component of the adjuvant 321 (Fig. 4 C, D) . All six fish vaccinated with Montanide ISA760VG adjuvant showed 322 inflammatory cell responses (Fig. 4 E, F) . Three fish had severe inflammatory cell 323 accumulations in a wide area of injection site around pancreas, intestine, liver and spleen. In 2 324 fish, the capsule of the spleen and liver was not obvious due to infiltrated inflammatory cells 325 accompanied by newly produced fibrous tissue in the capsule area, and these changes may 326 lead to adhesions of internal organs. Scoring of histological changes in the different groups is 327 shown in Table 4 . 328 continuous or pulsed release [28] . The use of vaccine adjuvants allows for a reduction in the 371 number of immunisations or the amount of antigen needed for immunisation. 372
Adjuvants are substances which enhance the immune response to an antigen [29] and 373 one of the most effective used in aquaculture is mineral oil [30, 31] 
